Chief Executive Officer
Raman Singh is Chief Executive Officer (CEO) of Juniper Biologics overseeing its global pharmaceutical operations.
Prior to Juniper, Raman was CEO for Mundipharma and its operations in Latin America, the Middle East Africa and the Asia Pacific as well as the company’s Global Consumer Healthcare business.
Before joining Mundipharma in October 2011, Raman served as vice-president of commercial operations for emerging markets at GSK. In his role, he oversaw all aspects of the brand’s commercial operations across its emerging markets. Raman has previously held positions at AbbVie as the regional director in Australia and New Zealand, and general manager for Korea, as well as various sales, marketing and strategy positions at Bayer.
Raman graduated with a Bachelors in Mechanical Engineering. He also holds Masters of Business Administration from Assumption University and a Masters in International Management from Thunderbird School of International Management.
Raman also sits on the board for Liquidia, a late-stage clinical bio pharmaceutical company focused on the development and commercialisation of novel products. He is the only non-USA based Board Member. During his term, he successfully oversaw the IPO in NASDAQ, USA on July 25th, 2016 as well as the acquisition of RareGen LLC, a portfolio company of PBM Capital Group.
A champion of digital healthcare, Raman also sits on the boards of Biofourmis Healthcare and Neuroglee Therapeutics.
Chief Financial Officer
Stephanie Huin joined the company as its Chief Financial Officer with full responsibilities for leading Juniper’s finance, supply chain and IT strategies on a global basis. She will report directly to Raman Singh, Chief Executive Office.
Stephanie has over 20 years of experiences in various industries, mainly in healthcare, medical, manufacturing and FMCG. In her last 3 roles, she spent 12 years in various regional finance and M&A leadership roles in Mundipharma, Stryker and Takeda regional offices. Being a strong believer of change, she has a strong track record in process re-engineering, implementation of key financial systems and business partnering driving sustainable business growth as well as building financial governance.
Stephanie graduated Manchester Business School with an MBA and is also a CPA in Singapore and FCCA.
Chief Human Resource Officer
Jenette Wong is the Chief Human Resource Officer (CHRO) of Juniper Biologics, overseeing its human resource function. She will be responsible for evolving the company’s HR strategy and operations, including talent management, recruitment, leadership development, compensation and benefits, as well as market HR support.
Jenette has more than 15 years’ diverse experience within HR business partnering, HR services, cultural development, organizational design, and process optimization in various industries mainly in Oil and Gas, Telecommunications and Agriculture.
She graduated from Royal Melbourne Institute of Technology with Bachelor of Business Administration.
Chief Commerical Officer
Benedict Ong is Chief Commercial Officer of Juniper Biologics overseeing its global marketing and commercial operations.
Prior to joining Juniper, Benedict has many years of commercial experiences in Pharmaceuticals, Next Generation Sequencing Diagnostics and Medical Devices focusing in the therapeutic area of oncology and haematology. He was holding to various local and regional sales and marketing positions in various established MNCs including Janssen and Roche.
Benedict graduated with a Bachelor in Pharmacy from National University of Singapore and is currently a registered pharmacist. He also holds a Master of Business Administration from the University of Birmingham.
Vice President Communications and Corporate Affairs
Stephenie is an accomplished and experienced global corporate communications and marketing professional with a proven track record in b2b and b2c marketing and communications across multiple industries including broadcasting, financial services and insurance. She has more than 20 years of proven expertise in Brand and PR strategy, issues and crisis management, reputation management, internal and change communications as well as marketing and sponsorship activation.
Prior to Juniper Biologics, Stephenie was Chief Communications Officer at Mundipharma. She has also held key strategic communications roles within the financial services sector. These included serving as the Head of Communications at Barclays as well as the Director of Communications for Aviva Asia.
She also previously led the regional marketing communications function for ESPN Star Sports as Vice President, spearheading rebranding and corporate positioning strategies for the organization, as well as at Media Monitors where she advised clients from the Singapore government as well as Fortune 500 companies on the effectiveness of their communications strategies.
Stephenie holds a Master of Science in Organizational Communications and a Bachelor of Science in Mass Communications and Journalism from Southern Illinois University.
Head of Legal and Compliance
Ewa Miszczak is Juniper Biologic’s Global Head of Legal.
Ewa is a General Counsel, Compliance Professional and Trainer with over 20 years’ experience gained in-house and in private legal practice.
Her experience includes managing legal and compliance teams across Asia Pacific, Middle East & Africa with various positions held across Legal, Compliance and HR functions in medical device and pharmaceutical companies. She has lived and worked in Australia and Singapore.
In her role at Juniper Biologics, Ewa has established the legal function and she has been supporting complex commercial contracting and negotiations, compliance, corporate governance and anti-corruption matters.
She gained her Legal and Commerce qualifications at Murdoch University in Perth, Western Australia.
Vice President and Chief Science Officer
Shunitra Chandra Segran is Chief Scientific Officer of Juniper Biologics overseeing its global medical and regulatory operations.
Shunitra has 16 years of pharmaceutical industry experience and 10 years of clinical practice experience. Prior to joining Juniper in Jan 2023, Shunitra was at Sanofi where she drove the strategic transformation of the consumer health science function across the globe for the last 3 years.
Shunitra’s technical expertise across medical, regulatory, clinical operations, quality, pharmacovigilance and launch excellence has enabled her to build scientific strategies for pharmaceutical medicines, vaccines, and consumer health portfolio businesses. Over the course of her career, she has also led large sized teams at an operational level across emerging markets including Africa, Middle East, Russia, Eurasia, India, China, Asia, Japan, Korea and Australia.
Shunitra is a qualified medical doctor with an M.B.B.S degree from Jawaharlal Nehru Medical College, Belgaum, Indi
Vice President and Regional General Manager of ANZ
Maulik Shroff serves as Vice President and General Manager for Juniper Biologics in Australia and New Zealand. He has more than 20 years experience in the pharmaceutical industry and has worked across geographies such as India, Australia and the Asia Pacific region.
Maulik graduated with a Bachelors of Science in Bio Chemistry from India and also holds a Masters of Engineering in Information Technology from RMIT University in Melbourne Australia.
He started his pharmaceutical journey in India working for Emcure in sales and sales management roles. He continued his career in Australia working for Eli Lilly, Novartis and Mundipharma prior to joining Juniper Biologics. Over these years Maulik has successfully worked in various commercial and leadership roles. His leadership has spanned over different therapeutic areas including oncology.
Maulik is passionate about building high performing teams to drive commercial innovation and improve patient outcomes.
Vice President and Regional General Manager of SEA
Suresh Pragasam serve as Vice President and Regional General Manager of Juniper Biologics overseeing its South East Asia pharmaceutical operations.
Prior to Juniper, Suresh was Regional General Manager for Mundipharma and its operations in South East Asia, HongKong and Taiwan.
Before joining Mundipharma in March 2016, Suresh served as Strategic Development Director and Commercial Director for Sanofi Pharmaceuticals. In his role, he oversaw all aspects of the company’s strategic formulations and operations, Business Development and Commercial Operations for the company’s pharmaceutical business across Malaysia and Singapore. Suresh has previously held positions at UCB Pharma and GlaxoSmithKline Pharmaceuticals as the Commercial Director for Malaysia and Singapore, as well as various sales, marketing and commercial Excellence positions at GlaxoSmithKline Pharmaceuticals.
Suresh graduated with a Masters in Business Administration from Edith Cowan University, Australia.
Vice President and Regional General Manager of MEA
Haytham Ramzy serves as Vice President & General Manager, Middle-East & Africa for Juniper Biologics.
Haytham has over 16 years of pharmaceutical experience where he is most recently the Cluster Head in Egypt and Near East. Haytham is a strategic and results-oriented leader with a successful track record in the pharmaceutical industry, partnering CEOs and Boards, leading stakeholder and employee engagement.
As Vice President & General Manager, MEA, Haytham will provide strategic direction to the region’s operations including all sales, marketing, reporting and compliance plans. He will be responsible for establishing Juniper Biologics operations and building long-term partnerships with healthcare professionals, patient groups and government bodies. He will be an important link between Juniper Biologics and channel partners in the MEA region, and will be accountable for all business development activities, with the aim of growing Juniper Biologics’ business portfolio.
Representative Director & President, Japan
Hajime Saijo (Jim) serves as the Representative Director & President, Japan, for Juniper Biologics. Jim will focus on leading and contributing to clinical development strategies and plans, protocols and clinical study reports, interacting with key global regulatory authorities, and directing all activities required to conducting and monitoring clinical trials while ensuring that Good Clinical Practices (GCP) are followed. He will collaborate cross-functionally to ensure the advancement of assets through the pipeline with a focus in helping to lead successful NDA submissions for its assets.
Jim brings with him over 36 years’ experience in pharmaceutical industry, and Research & Development specialisations. He had significant R&D leadership experience in leading Japanese CRO and MNC pharmaceutical companies, with a strong track record of successful launches and general management roles. He possesses both commercial acumen and a scientific background, having extensive background in Clinical Development, Regulatory, Medical Affairs, PV with a wide network of senior leaders of academia and government authorities.